Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins
Publikation: Beiträge in Zeitschriften › Zeitschriftenaufsätze › Forschung › begutachtet
Standard
in: Cancer Immunology, Immunotherapy , Jahrgang 53, Nr. 12, 12.2004, S. 1085-1092.
Publikation: Beiträge in Zeitschriften › Zeitschriftenaufsätze › Forschung › begutachtet
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins
AU - Pavlenko, Maxim
AU - Roos, Anna-Karin
AU - Leder, Christoph
AU - Hansson, L.O.
AU - Kiessling, Rolf
AU - Levitskaya, Elena
AU - Pisa, Pavel
N1 - Funding Information: Acknowledgements We thank Mr W David Culp Jr and Ms Ashley Miller for the critical assistance with preparation of the manuscript. This study was supported by the Cancer Society in Stockholm, the Swedish Cancer Society, Karolinska Institute Funds, Swedish Research Council, Wallenberg’s Foundation, and Swedish Society for Medical Research.
PY - 2004/12
Y1 - 2004/12
N2 - The ability of heat shock proteins (HSPs) to increase the potency of protein- and DNA-based vaccines has been previously reported. We have constructed several plasmid-based vectors encoding chimeric proteins containing prostate-specific antigen (PSA) fused to Mycobacterium tuberculosis hsp70, M. bovis hsp65, Escherichia coli DnaK (hsp70), or human hsp70. Immunizing mice with these plasmids induced CD8+ cytotoxic T lymphocytes (CTLs) specific to human PSA and protected mice from a subsequent subcutaneous challenge with PSA-expressing tumors. We did not observe a significant difference either in the levels of PSA-specific CTLs or in protection against tumor challenge in mice immunized with plasmids expressing PSA-HSP chimeric proteins, as compared to mice receiving a conventional PSA-expressing DNA plasmid. Our data indicate that using HSPs as fusion partners for tumor-specific antigens does not always result in the enhancement of antigen-specific CTL responses when applied in the form of DNA vaccines.
AB - The ability of heat shock proteins (HSPs) to increase the potency of protein- and DNA-based vaccines has been previously reported. We have constructed several plasmid-based vectors encoding chimeric proteins containing prostate-specific antigen (PSA) fused to Mycobacterium tuberculosis hsp70, M. bovis hsp65, Escherichia coli DnaK (hsp70), or human hsp70. Immunizing mice with these plasmids induced CD8+ cytotoxic T lymphocytes (CTLs) specific to human PSA and protected mice from a subsequent subcutaneous challenge with PSA-expressing tumors. We did not observe a significant difference either in the levels of PSA-specific CTLs or in protection against tumor challenge in mice immunized with plasmids expressing PSA-HSP chimeric proteins, as compared to mice receiving a conventional PSA-expressing DNA plasmid. Our data indicate that using HSPs as fusion partners for tumor-specific antigens does not always result in the enhancement of antigen-specific CTL responses when applied in the form of DNA vaccines.
KW - Biology
KW - CTL
KW - DNA vaccine
KW - heat shock protein
KW - prostate-specific antigen
UR - http://www.scopus.com/inward/record.url?scp=8644277992&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/6ef4a9e9-90c2-3136-9988-9e2dd5b1c4fa/
U2 - 10.1007/s00262-004-0559-z
DO - 10.1007/s00262-004-0559-z
M3 - Journal articles
VL - 53
SP - 1085
EP - 1092
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
SN - 1432-0851
IS - 12
ER -